UNSPSC 51182107: Conivaptan hydrochloride

This classification denotes a vasopressin antagonist with the molecular formula C32H26N4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75L57R6X36, chemically known as (1,1-biphenyl)-2-carboxamide, n-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)- but more generally known as conivaptan hydrochloride, which bears US NIH Compound Identifier 151171. Most nations, for tariff and trade purposes, schedule conivaptan hydrochloride under HS 29339930 and SITC 51577.

As of Q4 2014, CONIVAPTAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Conivaptan hydrochloride bears US NLM identifiers UMLS ID C1700196 and NCI Concept Code C65351. SMILES: CC1[NH]C-2C(N1)CCN(C3C2CCCC3)C(=O)C4CCC(CC4)NC(=O)C5CCCCC5C6CCCCC6.CL.

UNSPSC 51182107 Conivaptan hydrochloride is a Commodity code covering a vasopressin-receptor antagonist pharmaceutical used to treat hyponatremia in hospitalized patients. State and local governments procure this drug primarily through public health departments, hospital systems, and correctional health services for inpatient acute care settings where rapid sodium correction is clinically indicated. Purchasing typically occurs through competitive bid processes, group purchasing organization contracts, or state pharmaceutical formularies that establish pricing and supply agreements. The issuing bodies are primarily state health departments, county hospital systems, and municipal medical centers; school districts and transit authorities do not appear as buyers under this code.

The source provides no recent state and local contract opportunities tagged to UNSPSC 51182107. Without posted solicitations, RFPs, RFQs, IFBs, or ITBs in the available record, geographic concentration and representative opportunities cannot be characterized. Conivaptan hydrochloride procurement at the state and local level is typically managed through standing pharmaceutical contracts and formulary agreements rather than individual competitive procurements, which limits visibility into discrete opportunity activity. Firms pursuing this market should monitor state pharmaceutical director associations, group purchasing organization channels, and individual hospital system supply-chain RFQs rather than rely on traditional competitive notice channels.